It is expected that monoclonal antibodies targeted against cytokines deeply involved in the pathogenesis of AD, such as Th2 cytokines (IL-4, IL13, and IL-31), have the potential to be used as novel treatments for AD. The gene discussed is IL31; the disease is Alzheimer disease.